XtalPi Holdings Limited Co-Founders Voluntarily Extend Lock-Up Undertakings Until June 2027
Key Highlights:
- Co-founders of XtalPi Holdings Limited extend lock-up period for their shares by another year, signaling long-term confidence in the company.
- Total locked-up shares amount to 555,171,595, representing approximately 12.9% of the company’s issued share capital.
- Lock-up expiry date now set for 12 June 2027, extended from previous expiry of 12 June 2026.
- Shares include those held directly and indirectly by companies controlled by founders and QuantumPharm Roc Holdings Limited.
Details of the Lock-Up Extension
XtalPi Holdings Limited announced that its co-founders and executive directors—Dr. Wen Shuhao, Dr. Ma Jian, and Dr. Lai Lipeng—have voluntarily extended the lock-up undertakings for the shares they beneficially own. This move follows an earlier extension announced in May 2025, which had shifted the lock-up expiry from 12 June 2025 to 12 June 2026. Now, the expiry is further extended to 12 June 2027.
The lock-up undertakings cover a substantial block of shares: 555,171,595 shares, or approximately 12.9% of XtalPi’s issued share capital. These shares comprise those held directly and indirectly by companies controlled by each founder, as well as shares held by QuantumPharm Roc Holdings Limited. QuantumPharm Roc’s shares represent underlying outstanding options held by each founder, which will be transferred upon option exercise.
Potential Share Price Impact & Considerations for Investors
This announcement is potentially price sensitive for several reasons:
- Extended lock-up signals founder confidence: The voluntary extension is a strong signal of the co-founders’ belief in the company’s long-term prospects, which may increase investor trust and reduce perceived risk of large share sales in the near term.
- Reduced risk of major sell-off: With 12.9% of shares locked up until mid-2027, there is less risk of significant share price volatility caused by founders selling their holdings.
- Market stability: The extended lock-up can help support share price stability, as large blocks of shares will not enter the market unexpectedly.
- Underlying options structure: Shares held by QuantumPharm Roc are tied to options. Investors should monitor option exercises, though transfers are covered by the lock-up extension.
Board Composition Update
As of the date of the announcement, the Board consists of four executive directors (Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng, Dr. Jiang Yide Alan) and three independent non-executive directors (Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki, Mr. Chow Ming Sang).
Investor Advisory
Shareholders and potential investors are advised to exercise caution when dealing in the shares and other securities of XtalPi Holdings Limited, particularly in light of this significant lock-up extension.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information is based on the company’s official announcement and may be subject to change.
XtalPi Holdings有限公司創辦人自願延長鎖定承諾至2027年6月
重點摘要：
- XtalPi Holdings創辦人自願將股份鎖定期再延長一年，展現對公司長遠發展的信心。
- 鎖定股份總數為555,171,595股，約佔公司已發行股本的12.9%。
- 鎖定期現延至2027年6月12日，原本的到期日為2026年6月12日。
- 股份包括由創辦人控制的公司及QuantumPharm Roc Holdings Limited持有的股份。
鎖定期延長詳情
XtalPi Holdings宣布，公司三位創辦人及執行董事——溫樹浩博士、馬健博士、賴立鵬博士——自願延長其所持股份的鎖定承諾。此舉是繼2025年5月自願延長鎖定期後再次延長，鎖定期由2026年6月12日延至2027年6月12日。
鎖定承諾涵蓋大量股份：555,171,595股，約佔公司已發行股本的12.9%。這些股份包括創辦人直接或間接控制的公司持有股份，以及QuantumPharm Roc Holdings Limited持有的股份。QuantumPharm Roc的股份是創辦人未行使的期權，行使期權後將由QuantumPharm Roc轉讓給創辦人。
潛在股價影響及投資者須知
此公告可能對股價有影響，原因包括：
- 創辦人信心展現：自願延長鎖定期展示對公司長遠價值的信心，有機會提升投資者信任，降低短期大額拋售風險。
- 減少大額沽售風險：12.9%股份鎖定至2027年，有助穩定股價，減少因創辦人沽貨而造成的波動。
- 市場穩定：鎖定期延長有助支持股價穩定，大量股份不會突然流入市場。
- 期權結構：QuantumPharm Roc的股份與期權相關，投資者需留意期權行使情況，但轉讓也受鎖定承諾保障。
董事會組成更新
截至公告日期，董事會由四位執行董事（溫樹浩博士、馬健博士、賴立鵬博士、蔣一德博士）及三位獨立非執行董事（羅卓健先生、陳穎琪女士、周明生先生）組成。
投資者提示
公司股東及潛在投資者在買賣XtalPi Holdings股份及其他證券時需保持謹慎，尤其需注意此次鎖定期延長的重要信息。
免責聲明：本文僅供參考，不構成投資建議。投資者應自行做足功課並諮詢專業人士，作出明智投資決定。本文根據公司公告撰寫，資料如有更改，請以最新公告為準。
